7096 StemCell Institute - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

7096

TSE Growth

StemCell Institute

830

JPY

-10

(-1.19%)

Mar 13, 3:30 pm JST

5.20

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

840

Mar 13, 11:32 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	1,781	226	212	133	13.2	0	May 12, 2022	J-GAAP
Mar, 2023	2,091	297	300	198	19.3	0	May 11, 2023	J-GAAP
Mar, 2024	2,481	413	417	310	30.4	0	May 14, 2024	J-GAAP
Mar, 2025	2,679	418	428	385	37.7	25	May 13, 2025	J-GAAP
Mar, 2026 Guidance	3,000	450	450	320	31.8	0	Nov 12, 2025	J-GAAP
YoY	+12.0%	+7.7%	+5.1%	-16.9%	-15.6%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2022	Jun 25, 2021	1,706	200	196	136	0	J-GAAP
Results	May 12, 2022	1,781	226	212	133	0	J-GAAP
Mar, 2023	May 12, 2022	Available in future release
Results	May 11, 2023
Mar, 2024	May 11, 2023
Results	May 14, 2024
Mar, 2025	May 14, 2024
Results	May 13, 2025
Mar, 2026	May 13, 2025	3,000	450	450	320	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2015	715	－	Available in future release
Mar, 2016	754	+5.5
Mar, 2017	807	+7.0
Mar, 2018	861	+6.7
Mar, 2019	1,149	+33.4
Mar, 2020	1,676	+45.9
Mar, 2021	1,409	-15.9
Mar, 2022	1,781	+26.4
Mar, 2023	2,091	+17.4
Mar, 2024	2,481	+18.7
Mar, 2025	2,679	+8.0
Mar, 2026 Guidance	3,000	+12.0	450	+7.7	450	+5.1	31.8	-15.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	2,481	413	16.7	12.42	5.02	0.40	30.4
Mar, 2025	2,679	418	15.6	14.48	5.48	0.38	37.7
Mar, 2026 Guidance	3,000	450	15.0	12.03	3.99	0.37	31.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,679	418	428	385	37.7
Fiscal Year	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	1,055	134	136	88	8.6	0	May 11, 2023	J-GAAP
Oct - Mar, 2023	1,268	198	201	151	14.8	0	May 14, 2024	J-GAAP
Oct - Mar, 2024	1,306	160	164	114	11.2	0	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	1,585	320	314	236	23.4	0	Nov 12, 2025	J-GAAP
YoY	+21.4%	+100.0%	+91.5%	+107.0%	+110.2%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	297	-186	99	-285	0	3,324	57.20	J-GAAP
Mar, 2024	413	-477	334	-811	-1	2,845	43.48	J-GAAP
Mar, 2025	418	208	467	-259	146	3,200	42.67	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	1,884	356	358	254	24.9	85.9	Feb 7, 2024	J-GAAP
Apr - Dec, 2024	2,040	358	367	339	33.2	85.7	Feb 13, 2025	J-GAAP
Apr - Dec, 2025	2,144	218	228	146	14.5	50.7	Feb 12, 2026	J-GAAP
YoY	+5.1%	-39.1%	-37.9%	-56.9%	-56.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	597	57	59	56	5.5	9.5	May 14, 2024	J-GAAP
Apr - Jun, 2024	678	123	124	178	17.4	18.1	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	695	135	140	93	9.1	19.4	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	667	100	103	68	6.7	15.0	Feb 13, 2025	J-GAAP
Jan - Mar, 2025	639	60	61	46	4.5	9.4	May 13, 2025	J-GAAP
Apr - Jun, 2025	700	65	67	43	4.2	9.3	Aug 7, 2025	J-GAAP
Jul - Sep, 2025	715	65	69	41	4.1	9.1	Nov 12, 2025	J-GAAP
Oct - Dec, 2025	729	88	92	62	6.2	12.1	Feb 12, 2026	J-GAAP
YoY	+9.3%	-12.0%	-10.7%	-8.8%	-7.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	345	－	Available in future release
Apr - Jun, 2021	424	+30.5
Jul - Sep, 2021	441	+22.8
Oct - Dec, 2021	451	+18.7
Jan - Mar, 2022	465	+34.8
Apr - Jun, 2022	492	+16.0
Jul - Sep, 2022	544	+23.4
Oct - Dec, 2022	543	+20.4
Jan - Mar, 2023	512	+10.1
Apr - Jun, 2023	577	+17.3
Jul - Sep, 2023	636	+16.9
Oct - Dec, 2023	671	+23.6
Jan - Mar, 2024	597	+16.6
Apr - Jun, 2024	678	+17.5
Jul - Sep, 2024	695	+9.3
Oct - Dec, 2024	667	-0.6
Jan - Mar, 2025	639	+7.0
Apr - Jun, 2025	700	+3.2
Jul - Sep, 2025	715	+2.9
Oct - Dec, 2025	729	+9.3	88	-12.0	92	-10.7	6.2	-7.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	729	141	142	178	17.4
Fiscal Year	Dec, 2025	Dec, 2023	Dec, 2023	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	224.33	39.5	5,811	2,298	1,007	0.00	May 11, 2023	J-GAAP
Mar, 2024	262.78	41.1	6,543	2,692	1,318	0.00	May 14, 2024	J-GAAP
Mar, 2025	258.35	35.0	7,500	2,627	1,448	0.19	May 13, 2025	J-GAAP
Apr - Dec, 2025	ー	33.1	8,028	2,661	1,586	0.17	Feb 12, 2026	J-GAAP

StemCell Institute(7096) Financial Results